Cambridge, UK, 25 April 2006 – BioProgress (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, has signed a strategic partnership agreement with the pharmaceutical sales and marketing company, Cristers, for the promotion and distribution of its over-the-counter (OTC) SOLULEAVES™ products in France. 

The products that Cristers will market for BioProgress’ subsidiary, Dexo S.A. (Dexo) include the newly-launched Ronflux anti-snoring film strips, a range of vitamin, mineral, nutritional and herbal products and a licensed range of pharmaceutical OTC medicines. Each of these products uses BioProgress’ SOLULEAVES™ technology, in which active ingredients, colours and flavours are incorporated into a GMO-free, non-animal derived film, which dissolves in the mouth, releasing the active ingredients.  

With over 160 sales personnel based in Herblay, near Paris, France, and telemarketing and distribution systems in place, Cristers is well positioned to sell Dexo products in France. The Company was formed in 2005 by Stephane Joly, President of Cristers, with the backing of Investinov and Nepenthes. Investinov is France’s leading contract sales organisation with over 1200 medical representatives. Nepenthes is one of France’s largest retail pharmacist buying groups with over 22% of the market share.  

Richard Trevillion, CEO of BioProgress said: “This is an important strategic partnership for BioProgress. Cristers has excellent credentials and will provide Dexo with significant resources in the areas of pharmacy promotion, direct marketing and promotion to doctors. With the backing of France’s largest contract sales organisation, and the largest pharmacist buying group, Cristers will be able to rapidly expand the Dexo sales coverage in France. Our confidence in the Cristers management team, has led us to commit to a long-term strategic partnership.” 

BioProgress launched two of its SOLULEAVES™ products, Ronflux strips and caffeine strips, via Dexo at Pharmagora 2006, an annual French retail pharmacists’ trade show, earlier this month. Due to the positive response to these products at the show, BioProgress has accelerated its development and launch programmes for all its SOLULEAVES™ products, to meet the anticipated demand. These products are manufactured at the BioProgress group’s cGMP accredited facility based in Tampa, Florida, USA. 

For further information please contact: 

BioProgress plc	+44 (0)1223 3944250
Richard Trevillion, Chief Executive Officer
Northbank Communications	+44 (0)207 886 8150
Sue Charles Gemma Bradley Justine Lamond

About BioProgress plc:

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London’s AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGEL™ polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934.  To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may vary materially from the expectations contained in the forward-looking statements.  The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation.  Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company’s filings with the Securities and Exchange Commission.  The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.  This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice.  The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law.  Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions. 

-ENDS-